Zydus Lifesciences publishes phase 3 results of research molecule, Desidustat
Zydus Lifesciences announced the publication of two manuscripts detailing the DREAM-ND and DREAM-D Phase 3 study results of Desidustat, a novel HIF-PH inhibitor in the prestigious American Journal of Nephrology.